DIVISLAB — Divi's Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Divi's Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	69,694	89,598	77,675	78,450	93,600
Cost of Revenue
Gross Profit	42,186	54,706	40,787	40,860	50,120
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	43,547	53,874	57,417	60,140	67,900
Operating Profit	26,147	35,725	20,258	18,310	25,700
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	26,660	36,835	23,686	21,630	29,160
Provision for Income Taxes
Net Income After Taxes	19,843	29,605	18,234	16,000	21,910
Net Income Before Extraordinary Items
Net Income	19,843	29,605	18,234	16,000	21,910
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	19,843	29,605	18,234	16,000	21,910
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	74.9	112	68.7	60.4	82.6
Dividends per Share